# Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference Canonical URL: https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-at-the-2026-jefferies-global-healthcare-conference Ticker: KPTI Company: Karyopharm Therapeutics Source: Karyopharm Therapeutics Published: 2026-06-25 13:46 EST Original Source URL: https://investors.karyopharm.com ## Summary Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate... ## Article Body Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference Click here to print this page. Click here to send us an email. Click here to open PDF. , / PRNewswire / -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2026 Jefferies Global Healthcare Conference in a fireside chat on Thursday, June 4, 2026 at 8:10 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website, http://investors.karyopharm.com/events-presentations , and will be available for replay following the event. About Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com , and follow us on LinkedIn and on X at @Karyopharm. XPOVIO ® and NEXPOVIO ® are registered trademarks of Karyopharm Therapeutics Inc. SOURCE Karyopharm Therapeutics Inc. For further information: Investors - Brendan Strong, Senior Vice President, Investor Relations, 617.762.2661, brendan.strong@karyopharm.com; Media - Mary Ann Ondish, Head of Corporate Communications, 914.552.4625, Maryann.ondish@karyopharm.com ## Recent Company News - 2026-07-01 20:05 EST — [Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-cc27221e) — Source: Karyopharm Therapeutics - 2026-06-25 13:46 EST — [Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026](https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-in-webcast-featuring-endometrial-cancer-key-opinion-leader-on-june-8-2026) — Source: Karyopharm Therapeutics - 2026-06-25 13:46 EST — [Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026](https://biopharmsignal.com/news/KPTI/karyopharm-s-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-selected-for-late-breaking-oral-presentation-at-eha-2026) — Source: Karyopharm Therapeutics - 2026-06-25 13:46 EST — [Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology](https://biopharmsignal.com/news/KPTI/karyopharm-to-present-results-from-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-in-late-breaking-oral-presentation-at-asco-2026-with-simultaneous-publication-in-the-journal-of-clinical-oncology) — Source: Karyopharm Therapeutics - 2026-06-25 13:46 EST — [Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Karyopharm Therapeutics ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)